ArticleESMO open2026

Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.

S M Tolaney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.